dc.contributor.author | Hijab, A | |
dc.contributor.author | Curcean, S | |
dc.contributor.author | Tunariu, N | |
dc.contributor.author | Tovey, H | |
dc.contributor.author | Alonzi, R | |
dc.contributor.author | Staffurth, J | |
dc.contributor.author | Blackledge, M | |
dc.contributor.author | Padhani, A | |
dc.contributor.author | Tree, A | |
dc.contributor.author | Stidwill, H | |
dc.contributor.author | Finch, J | |
dc.contributor.author | Chatfield, P | |
dc.contributor.author | Perry, S | |
dc.contributor.author | Mu Koh, D | |
dc.contributor.author | Hall, E | |
dc.contributor.author | Parker, C | |
dc.date.accessioned | 2021-05-04T14:56:22Z | |
dc.date.available | 2021-05-04T14:56:22Z | |
dc.date.issued | 2021-10-01 | |
dc.identifier.citation | Clinical Genitourinary Cancer, 2021 | |
dc.identifier.issn | 1558-7673 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4537 | |
dc.identifier.doi | 10.1016/j.clgc.2021.03.020 | |
dc.description.abstract | BACKGROUND: Radium-223 is a bone-seeking, alpha-emitting radionuclide used in metastatic castration-resistant prostate cancer (mCRPC). Radium-223 increases the risk of fracture when used in combination with abiraterone and prednisolone. The risk of fracture in men receiving radium-223 monotherapy is unclear. PATIENTS AND METHODS: This was a prospective, multicenter phase II study of radium-223 in 36 men with mCRPC and a reference cohort (n = 36) matched for fracture risk and not treated with radium-223. Bone fractures were assessed using whole-body magnetic resonance imaging. The primary outcome was risk of new fractures. RESULTS: Thirty-six patients were treated with up to six 4-week cycles of radium-223. With a median follow-up of 16.3 months, 74 new fractures were identified in 20 patients. Freedom from fracture was 56% (95% confidence interval, 35.3-71.6) at 12 months. On multivariate analysis, prior corticosteroid use was associated with risk of fracture. In the reference cohort (n = 36), 16 new fractures were identified in 12 patients over a median follow-up of 24 months. Across both cohorts, 67% of all fractures occurred at uninvolved bone. CONCLUSIONS: Men with mCRPC, and particularly those treated with radium-223, are at risk of fracture. They should receive a bone health agent to reduce the risk of fragility fractures. | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | CIG MEDIA GROUP, LP | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-03-27 | |
rioxxterms.version | AM | |
rioxxterms.versionofrecord | 10.1016/j.clgc.2021.03.020 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Clinical Genitourinary Cancer | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Trials & Statistics Unit | |
icr.researchteam | Clinical Trials & Statistics Unit | |
dc.contributor.icrauthor | Tovey, Holly | |
dc.contributor.icrauthor | Blackledge, Matthew | |
dc.contributor.icrauthor | Hall, Emma | |